Cost-utility analyses in diabetes: A systematic review and implications from real-world evidence

Value in Health

Volumn 18, Issue 2, 2015, Pages 308-314

  Zhong, Yue ^a   Lin, Pei Jung ^a   Cohen, Joshua T ^a   Winn, Aaron N ^b   Neumann, Peter J ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b University of North Carolina at Chapel Hill   (United States)

Author keywords

cost utility analysis; diabetes; health care utilization; systematic review

Indexed keywords

INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; METFORMIN PLUS PIOGLITAZONE; METFORMIN PLUS REPAGLINIDE; METFORMIN PLUS ROSIGLITAZONE; NATEGLINIDE; REPAGLINIDE;

COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIABETES MELLITUS; ELECTRONIC MEDICAL RECORD; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE INDUSTRY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH EDUCATION; HEALTH SERVICE; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REGISTER; REVIEW; SYSTEMATIC REVIEW; COST BENEFIT ANALYSIS; ECONOMICS; PROCEDURES;

COST-BENEFIT ANALYSIS; DIABETES MELLITUS; ELECTRONIC HEALTH RECORDS; HUMANS; QUALITY-ADJUSTED LIFE YEARS; REGISTRIES;

EID: 84924968676     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2014.12.004     Document Type: Review

References (36)

1. American Diabetes Association Economic costs of diabetes in the U.S. in 2012 Diabetes Care 36 2013 1033 1046
2. T.M. Dall, Y. Zhang, and Y.J. Chen The economic burden of diabetes Health Aff (Millwood) 29 2010 297 303
3. Centers for Disease Control and Prevention. National diabetes fact sheet, 2011. Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf. [Accessed December 1, 2013].
4. D.C. Klonoff, and D.M. Schwartz An economic analysis of interventions for diabetes Diabetes Care 23 2000 390 404
5. P. Zhang, M.M. Engelgau, and S.L. Norris Application of economic analysis to diabetes and diabetes care Ann Intern Med 140 2004 972 977
6. M. Raikou, and A. McGuire The economics of screening and treatment in type 2 diabetes mellitus Pharmacoeconomics 21 2003 543 564
7. S.M.C. Vijgen, M. Hoogendoorn, and C.A. Baan Cost effectiveness of preventive interventions in type 2 diabetes mellitus: a systematic literature review Pharmacoeconomics 24 2006 425 441
8. R. Li, P. Zhang, and L.E. Barker Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review Diabetes Care 33 2010 1872 1894
9. M.R. Gold Cost-Effectiveness in Health and Medicine 1996 Oxford University Press New York
10. M.F. Drummond, and T.O. Jefferson Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party BMJ 313 1996 275 283
11. M.F. Drummond, W.S. Richardson, and B.J. O'Brien Users' guides to the medical literature, XIII: how to use an article on economic analysis of clinical practice. A. Are the results of the study valid? Evidence-Based Medicine Working Group JAMA 277 1997 1552 1557
12. M.F. Drummond, M.J. Sculpher, and G.W. Torrance Methods for the Economic Evaluation of Health Care Programmes 3rd ed. 2005 Oxford University Press New York 1
13. D. Menon, F. Schubert, and G.W. Torrance Canada's new guidelines for the economic evaluation of pharmaceuticals Med Care 34 1996 DS77 DS86
14. B.J. O'Brien, D. Heyland, and W.S. Richardson Users' guides to the medical literature, XIII: how to use an article on economic analysis of clinical practice. B. What are the results and will they help me in caring for my patients? JAMA 277 1997 1802 1806
15. Task Force on Principles for Economic Analysis of Health Care Technology Economic analysis of health care technology: a report on principles Ann Intern Med 123 1995 61 70
16. Y. Handelsman, J.I. Mechanick, and L. Blonde American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan Endocr Pract 17 Suppl. 2 2011 1 53
17. American Diabetes Association Standards of medical care in diabetes-2012 Diabetes Care 35 Suppl. 1 2012 S11 S63
18. P.J. Neumann, C.-H. Fang, and J.T. Cohen 30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement Pharmacoeconomics 27 2009 861 872
19. J.D. Chambers, J. Lord, and J.T. Cohen Illustrating potential efficiency gains from using cost-effectiveness evidence to reallocate Medicare expenditures Value Health 16 2013 629 638
20. A.J. Palmer, S. Roze, and M. Lammert Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes Curr Med Res Opin 20 Suppl. 1 2004 S41 S51
21. W.J. Valentine, A.J. Palmer, and K.M. Erny-Albrecht Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH Adv Ther 23 2006 191 207
22. M. St Charles, M.E. Minshall, and B.J. Pandya A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US Curr Med Res Opin 25 2009 1343 1353
23. CDC Diabetes Cost-effectiveness Group Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes JAMA 287 2002 2542 2551
24. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 BMJ 317 1998 703 713
25. P. Raskin, L. Klaff, and J. McGill Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin Diabetes Care 26 2003 2063 2068
26. T.R. Pieber, H.-C. Treichel, and B. Hompesch Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy Diabet Med 24 2007 635 642
27. Y.K. Loke, C.S. Kwok, and S. Singh Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies BMJ 342 2011 d1309
28. G. Derosa, A. D'Angelo, and P.D. Ragonesi Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome J Clin Pharm Ther 31 2006 375 383
29. P.J. Neumann, A.B. Rosen, and D. Greenberg Can we better prioritize resources for cost-utility research? Med Decis Making 25 2005 429 436
30. C.M. Bell Bias in published cost effectiveness studies: systematic review BMJ 332 2006 699 703
31. C. McCabe, K. Claxton, and A.J. Culyer The NICE cost-effectiveness threshold: what it is and what that means Pharmacoeconomics 26 2008 733 744
32. J.P. Orlowski, and L. Wateska The effects of pharmaceutical firm enticements on physician prescribing patterns: there's no such thing as a free lunch Chest 102 1992 270 273
33. G.T. Schumock, S.M. Walton, and H.Y. Park Factors that influence prescribing decisions Ann Pharmacother 38 2004 557 562
34. E. Adang, L. Voordijk, and G. Jan van der Wilt Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions Health Policy 74 2005 146 156
35. H.-G. Eichler, S.X. Kong, and W.C. Gerth Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 7 2004 518 528
36. P.J. Neumann, H.R. Auerbach, and J.T. Cohen Low-value services in value-based insurance design Am J Manag Care 16 2010 280 286